A Phase 1/2 interventional study of LY3884961 and Methylprednisolone in Gaucher Disease, Type 2, sponsored by Prevail Therapeutics. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.
Among the 92 studies in Gaucher Disease with a site in United States, this one is the 46th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2021, is one of 6 in phase 1/2, reaches primary completion later than 9 of the 25 other live ones, and was the 68th registered.
177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.
Browse Gaucher Disease studies →20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 40+ · Healthy volunteers
Yale University · Sites in United States
Ages 3 mo–75 yrs
Spur Therapeutics · Sites in United States, Argentina, Australia and 7 more countries
Ages 18+
xCures · Sites in United States
Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Sites in United States
Ages 5–21 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 0 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 12 · Phase 4 6
First in 1988; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 20 across 100 interventional studies indexed under Gaucher Disease.
Median enrollment 30 across the 51 interventional studies, 60 across the 39 observational. Of the 50 that completed or were terminated, 20 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 92 have an industry lead sponsor. The 10 most frequent:
This study is registered under Prevail Therapeutics, one of the names counted as Eli Lilly and Company. Under that name alone:
Prevail Therapeutics is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Eli Lilly and Company has 3 studies filed under Gaucher Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Gaucher Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT02437396University of MinnesotaOxidative Stress and Inflammatory Biomarkers in Gaucher Disease | 2026-12-31 |
| NCT05586243University of MinnesotaMAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3) | 2026-12-31 |
| NCT05843552University of MinnesotaExtracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease | 2026-12-31 |
| NCT04411654Prevail TherapeuticsPhase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Gaucher Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus · Drug: Prednisone
Genetic: LY3884961 · Drug: Methylprednisolone · Drug: Sirolimus · Drug: Prednisone
Participants will receive a single dose of LY3884961 administered intracisternally.
Single IV pulse administered as concomitant medication.
Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
Administered orally as concomitant medication, followed by dose tapering.
Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation
Time frame: Year 5
Immunogenicity of AAV9 and GCase in blood
Time frame: Up to Year 2
Immunogenicity of AAV9 and GCase in CSF
Time frame: Up to Year 1
Time to death
Time frame: Baseline until event or study completion, up to Year 5
Time to clinical event
Clinical event defined as tracheostomy/invasive ventilation, and/or percutaneous endoscopic gastrostomy (PEG) tube placement, and/or nasogastric (NG) tube placement
Time frame: Baseline until event or study completion, up to Year 5
Change in cognitive function
Measured using Bayley Scales of Infant and Toddler Development (BSID-III)
Time frame: Months 6,12 and up to Year 2
Change in cognitive function
Measured using Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) as appropriate. (Not all patients begin the study at birth. Only patients who are age 36 months at the designated study visits will be assessed using this measure)
Time frame: Study Month 12 and up to Study Year 2
Change in motor skills
Change from baseline in motor function using Gross Motor Function Measure (GMFM-88).
Time frame: Months 6, 12 and up to Year 2
Change in motor skills
Change from baseline in motor function using the BSID-III.
Time frame: Months 6, 12 and up to Year 2
Change in Clinical Global Impressions (Severity)
Change from baseline in the clinical severity of illness (CGI-Severity {CGI-S}).
Time frame: Months 6, 12 and up to Year 2
Clinical Global Impressions (Improvement)
Clinical improvement from baseline (CGI-Improvement \[CGI-I\]).
Time frame: Months 6, 12 and up to Year 2
Change in adaptive behavior and functioning
Change from baseline in adaptive functioning using the Vineland Adaptive Behavior Scale (VABS-2) (2nd edition)
Time frame: Months 6 and 12 and up to Year 2
Change in most troubling symptoms
Change from baseline in the Visual Analog Scale for the Most Troubling Symptoms (VAS-MTS)
Time frame: Months 6, 12 and up to Year 2
Change in behavioral symptoms
Change from baseline in the Child Behavior Checklist (CBCL)
Time frame: Months 6, 12 and up to Year 2
Change in GCase (glucocerebrosidase) enzyme activity levels in blood
Time frame: Up to Year 5
Change in GCase enzyme activity levels in CSF (cerebrospinal fluid)
Time frame: Up to Year 3
Change in glycolipid levels in blood
Time frame: Up to Year 5
Change in glycolipid levels in CSF
Time frame: Up to Year 3
Individual Vector Shedding data
Time frame: Up to Year 5
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Feb 2027, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methylprednisolone · Sirolimus · Prednisone